⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer

Official Title: Phase III Multicentric Trial Comparing Accelerated Partial Breast Irradiation (APBI) Versus Standard or Hypofractionated Whole Breast Irradiation in Low Risk of Local Recurrence of Breast Cancer

Study ID: NCT01247233

Study Description

Brief Summary: The standard treatment for localized breast cancer is based on conservative surgery (when possible) followed by radiation therapy (RT) delivered to the whole breast. The recommended total RT dose is 45 to 50 Gy delivered in 4.5 to 5 weeks followed by a 10 to 16 Gy boost to the tumor bed for 1 to 1.5 weeks. The rationale for the development of APBI was based on the difficulty for many patients to reach RT centers to receive standard whole breast irradiation (WBI) after conservative surgery. APBI offers decreased overall treatment time and several theoretical advantages over WBI, including a decrease in dose delivered to uninvolved portions of the breast and adjacent organs. If equivalence between the two treatments can be shown, then APBI will be considered as a historic evolution in breast cancer management. In this phase III trial, designed in postmenopausal women \>50 years of age, the objective is to compare the effectiveness and safety of APBI compared with whole breast irradiation. This study is also designed to ensure high quality criteria for surgery, pathology and RT techniques in the 3 arms and will allow to provide data on economics and costs.

Detailed Description: Following breast conservative surgery, patients will be stratified according to the following prognostic factors using a minimisation technique: age (\<70 vs ≥70), HER2 status (HER2+ vs HER2-), hormonal receptor status (RH+ vs RH-) and lymph node invasion (pN0 vs pN0i+). Patients will be allocated to receive either standard treatment, hypofractionated treatment or APBI. Radiation therapy should be started between 4 and 12 weeks after the last surgery. Patients treated with standard whole breast irradiation will receive a total dose of 50 Gy in 25 fractions, 2 Gy per day, 5 days a week. The boost of 16 Gy will be delivered in 8 fractions for all patients after completion of the 50 Gy, without interruption. All patients will receive one fraction per day, 5 fractions a week. Patients treated with hypofractionated irradiation will receive a total dose of either 40 Gy (in 15 fractions, 2.66 Gy per day) or 42.5 Gy (in 16 fractions, 2.65 Gy per day) 5 days a week. Patients treated with APBI will receive a total dose of 40 Gy in 10 fractions, delivered twice a day over a time period of 5-7 days. Each daily dose must be separated by 6 hours. Patients will be followed at 3 and 6 month after the last dose of irradiation, at 12 months after the date of last surgery and then on a yearly basis during 10 years.

Eligibility

Minimum Age: 50 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Centre de traitement des Hautes energie - Clinique de l'Europe, Amiens, , France

Centre Hospitalier Universitaire, Amiens, , France

Institut Bergonié, Bordeaux, , France

Centre Hospitalier, Brive, , France

Centre Francois Baclesse, Caen, , France

CH Chambery, Chambery, , France

Hopital Henri Mondor, Creteil, , France

Centre Leonard de Vinci, Dechy, , France

CHU Michallon, Grenoble, , France

Hôpital Robert Boulin, Libourne, , France

Centre Oscar Lambret, Lille, , France

CHU Dupuytren, Limoges, , France

Centre Léon Bérard, Lyon, , France

Institut Paoli Calmettes, Marseille, , France

Clinique du Pont de Chaume, Montauban, , France

CRLC Val d'Aurelle, Montpellier, , France

Centre Hospitalier, Montélimar, , France

Centre Hospitalier de Mulhouse, Mulhouse, , France

Centre d'Oncologie de Gentilly, Nancy, , France

Clinique Hartmann, Neuilly sur Seine, , France

Centre de Haute Energie, Nice, , France

Groupe Hospitalier Pitié Salpétrière, Paris, , France

Hopital Tenon, Paris, , France

Saint Louis Hospital, Paris, , France

Centre Catalan d'Oncologie, Perpignan, , France

Institut Jean Godinot, Reims, , France

Centre Eugène Marquis, Rennes, , France

CH de Roanne, Roanne, , France

Centre Henri Becquerel, Rouen, , France

Institut de Cancérologie de la Loire, Saint Priest en Jarez, , France

Centre Paul Stauss, Strasbourg, , France

Centre Marie Curie, Valence, , France

Centre Alexis Vautrin, Vandoeuvre les Nancy, , France

Institut Gustave Roussy, Villejuif, , France

Contact Details

Name: Yazid Belkacemi, MD PhD

Affiliation: Henri Mondor Hospital AP-HP, Créteil, France

Role: PRINCIPAL_INVESTIGATOR

Name: Eric Lartigau, MD

Affiliation: Oscar Lambret Hospital, Lille, France

Role: PRINCIPAL_INVESTIGATOR

Name: Céline Bourgier, MD

Affiliation: Institut de Cancérologie de Montpellier, Montpellier, France

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: